FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560492061> ?p ?o ?g. }

• W2560492061 endingPage "1375" @default.
• W2560492061 startingPage "1375" @default.
• W2560492061 abstract "Abstract Background: Acute Myeloid Leukemia (AML) is an incurable disease characterized by a highly unstable genome, resulting in large-scale changes at diagnosis, as well as further evolution contributing to disease progression. However, the mechanisms whereby tumor cells adapt to genomic instability are largely unknown, but recent observations have correlated these abnormalities with dysfunctional DNA damage repair (DDR) machinery. SIRT6 is an important regulator of cellular stress response and genomic integrity. Here we investigated the role of this NAD+ -dependent deacetylase in regulating ongoing DNA damage observed in AML patients. Methods: SIRT6 mRNA level was determined by RT-qPCR in AML patients (n=100) diagnosed at the Hematology Department of University of Genoa (Italy), compared with normal bone marrow derived CD34+ cells (n=5). Correlation studies with clinical and molecular characteristics of these patients were also performed. A panel of different AML cell lines and primary cells, both sensitive and resistant to conventional and novel anti-AML therapies, was used in the study. The anti-leukemic effect of DNA-damaging agents (DDAs) including idarubicin, Ara-C and fludarabine was evaluated in presence of SIRT6 depletion/inhibition by CTG assay and Annexin-V/propidium iodide staining. Mechanistic studies were performed with Western-blotting, lentivirus-mediated shRNAs and immunofluorescence assay. Analysis of DNA DSB repair was done using chromosomally integrated reporter constructs, followed by cytometer analysis. Results: AML patients were grouped into lower and higher SIRT6 expressers according to its median mRNA level. Patients with lower expression had a higher incidence of FLT3-ITD (p=0.034, Wilcoxon signed rank test). No significant association was observed with respect to mutations of NPM1, nor with WT1 and BAALC expression. SIRT6 expression correlated also with adverse clinical outcome in term of event free and overall survival (p=0.035 and p=0.025, respectively; unpaired t test). Based on these data, we evaluated SIRT6 role in biology of AML. We found higher SIRT6 protein level in AML cell lines carrying FLT3-ITD mutation (MOLM-14 and MV 4-11) compared to cell lines harboring other mutations (OCI-AML3, THP-1, KG, NB4, HL60, Nomo1 and U937). Targeting SIRT6 by specific shRNAs weakly reduced AML cell survival compared with control-scrambled cells, by impairing DNA repair efficiency. Indeed, a restricted effect of SIRT6 impairment on DNA damage proteins (H2AX, RAD51, 53BP1, RPA32) was measured. We next examined the therapeutic relevance of SIRT6 inhibition in AML by testing effects of its depletion in combination with genotoxic agents. Remarkably, SIRT6 depletion conferred increased sensitivity of AML cells to idarubicin, Ara-C and Fludarabine. Overall, enhancing genotoxic stress while concomitantly blocking DNA double-strand breaks (DSBs) repair response, may represents an innovative strategy to increase chemosensitivity of AML cells. Further mechanistic studies revealed that SIRT6 acts as a genome guardian in leukemia cells by binding DNA damage sites and activating DNA-PKcs and CtIP by deacetylation, which in turn promotes DNA repair. Conclusion: Genomic instability is present in all hematologic malignancies including AML. Strategies aimed to shift the balance towards high DNA damage and reduced DNA repair by SIRT6 inhibition can decrease AML growth and may benefit patients with otherwise unfavorable outcomes. Disclosures No relevant conflicts of interest to declare." @default.
• W2560492061 created "2016-12-16" @default.
• W2560492061 creator A5004633066 @default.
• W2560492061 creator A5006211032 @default.
• W2560492061 creator A5006684853 @default.
• W2560492061 creator A5009267255 @default.
• W2560492061 creator A5015539158 @default.
• W2560492061 creator A5018088896 @default.
• W2560492061 creator A5028704583 @default.
• W2560492061 creator A5048224601 @default.
• W2560492061 creator A5050697704 @default.
• W2560492061 creator A5051459207 @default.
• W2560492061 creator A5056530572 @default.
• W2560492061 creator A5062694802 @default.
• W2560492061 creator A5066888430 @default.
• W2560492061 creator A5068251696 @default.
• W2560492061 creator A5078922292 @default.
• W2560492061 creator A5080844744 @default.
• W2560492061 creator A5084040459 @default.
• W2560492061 creator A5086845182 @default.
• W2560492061 date "2015-12-03" @default.
• W2560492061 modified "2023-10-01" @default.
• W2560492061 title "A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia" @default.
• W2560492061 doi "https://doi.org/10.1182/blood.v126.23.1375.1375" @default.
• W2560492061 hasPublicationYear "2015" @default.
• W2560492061 type Work @default.
• W2560492061 sameAs 2560492061 @default.
• W2560492061 citedByCount "1" @default.
• W2560492061 countsByYear W25604920612018 @default.
• W2560492061 crossrefType "journal-article" @default.
• W2560492061 hasAuthorship W2560492061A5004633066 @default.
• W2560492061 hasAuthorship W2560492061A5006211032 @default.
• W2560492061 hasAuthorship W2560492061A5006684853 @default.
• W2560492061 hasAuthorship W2560492061A5009267255 @default.
• W2560492061 hasAuthorship W2560492061A5015539158 @default.
• W2560492061 hasAuthorship W2560492061A5018088896 @default.
• W2560492061 hasAuthorship W2560492061A5028704583 @default.
• W2560492061 hasAuthorship W2560492061A5048224601 @default.
• W2560492061 hasAuthorship W2560492061A5050697704 @default.
• W2560492061 hasAuthorship W2560492061A5051459207 @default.
• W2560492061 hasAuthorship W2560492061A5056530572 @default.
• W2560492061 hasAuthorship W2560492061A5062694802 @default.
• W2560492061 hasAuthorship W2560492061A5066888430 @default.
• W2560492061 hasAuthorship W2560492061A5068251696 @default.
• W2560492061 hasAuthorship W2560492061A5078922292 @default.
• W2560492061 hasAuthorship W2560492061A5080844744 @default.
• W2560492061 hasAuthorship W2560492061A5084040459 @default.
• W2560492061 hasAuthorship W2560492061A5086845182 @default.
• W2560492061 hasBestOaLocation W25604920611 @default.
• W2560492061 hasConcept C126322002 @default.
• W2560492061 hasConcept C134935766 @default.
• W2560492061 hasConcept C143425029 @default.
• W2560492061 hasConcept C153911025 @default.
• W2560492061 hasConcept C190283241 @default.
• W2560492061 hasConcept C203014093 @default.
• W2560492061 hasConcept C2775934118 @default.
• W2560492061 hasConcept C2776694085 @default.
• W2560492061 hasConcept C2776755627 @default.
• W2560492061 hasConcept C2778041864 @default.
• W2560492061 hasConcept C2778461978 @default.
• W2560492061 hasConcept C2778729363 @default.
• W2560492061 hasConcept C2779117419 @default.
• W2560492061 hasConcept C2779263901 @default.
• W2560492061 hasConcept C2781021840 @default.
• W2560492061 hasConcept C31573885 @default.
• W2560492061 hasConcept C502942594 @default.
• W2560492061 hasConcept C54355233 @default.
• W2560492061 hasConcept C552990157 @default.
• W2560492061 hasConcept C71924100 @default.
• W2560492061 hasConcept C86803240 @default.
• W2560492061 hasConceptScore W2560492061C126322002 @default.
• W2560492061 hasConceptScore W2560492061C134935766 @default.
• W2560492061 hasConceptScore W2560492061C143425029 @default.
• W2560492061 hasConceptScore W2560492061C153911025 @default.
• W2560492061 hasConceptScore W2560492061C190283241 @default.
• W2560492061 hasConceptScore W2560492061C203014093 @default.
• W2560492061 hasConceptScore W2560492061C2775934118 @default.
• W2560492061 hasConceptScore W2560492061C2776694085 @default.
• W2560492061 hasConceptScore W2560492061C2776755627 @default.
• W2560492061 hasConceptScore W2560492061C2778041864 @default.
• W2560492061 hasConceptScore W2560492061C2778461978 @default.
• W2560492061 hasConceptScore W2560492061C2778729363 @default.
• W2560492061 hasConceptScore W2560492061C2779117419 @default.
• W2560492061 hasConceptScore W2560492061C2779263901 @default.
• W2560492061 hasConceptScore W2560492061C2781021840 @default.
• W2560492061 hasConceptScore W2560492061C31573885 @default.
• W2560492061 hasConceptScore W2560492061C502942594 @default.
• W2560492061 hasConceptScore W2560492061C54355233 @default.
• W2560492061 hasConceptScore W2560492061C552990157 @default.
• W2560492061 hasConceptScore W2560492061C71924100 @default.
• W2560492061 hasConceptScore W2560492061C86803240 @default.
• W2560492061 hasIssue "23" @default.
• W2560492061 hasLocation W25604920611 @default.
• W2560492061 hasOpenAccess W2560492061 @default.
• W2560492061 hasPrimaryLocation W25604920611 @default.
• W2560492061 hasRelatedWork W1968865933 @default.
• W2560492061 hasRelatedWork W2151584191 @default.
• W2560492061 hasRelatedWork W2157706504 @default.

• next